Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Illustration descripting the potential mechanism by which bevacizumab may exacerbate pulmonary hypertension.

Data availability

The data presented in this study are available in this article.

References

  1. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469–73. https://doi.org/10.1016/s1084-2756(03)00119-2

    Article  PubMed  Google Scholar 

  2. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515–26. https://doi.org/10.1056/NEJMra1208129

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group, B-RC. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15. https://doi.org/10.1056/NEJMoa1007374

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Hard AL, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment—a review. Acta Paediatr. 2011;100:1523–7. https://doi.org/10.1111/j.1651-2227.2011.02445.x

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327–33. https://doi.org/10.1016/j.ajo.2011.07.005. e321

    CAS  Article  PubMed  Google Scholar 

  6. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol. 2002;283:L555–62. https://doi.org/10.1152/ajplung.00408.2001

    Article  PubMed  Google Scholar 

  7. Liotta M, Rose PG, Escobar PF. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. Gynecol Oncol. 2009;115:308–9. https://doi.org/10.1016/j.ygyno.2009.08.003

    Article  PubMed  Google Scholar 

  8. Doxey S, Radwan A, Nyp MF. Outcomes of infants with severe ROP at risk of treatment with Avastin compared to laser surgery, https://scholarlyexchange.childrensmercy.org/cgi/viewcontent.cgi?article=1195&context=researchdays. 2021.

  9. Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol. 2010;661:323–35. https://doi.org/10.1007/978-1-60761-500-2_21

    CAS  Article  PubMed  Google Scholar 

  10. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology. 2007;91:283–90.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the funding sources. This work was supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 5 R01 HD072929 09 (SL), Children’s Miracle Network Grant at UC Davis Children’s Hospital (DS).

Author information

Authors and Affiliations

Authors

Contributions

LP drafted the initial manuscript. LP, LD, SL, and DS contributed to the concept, design, reviewed, and revised the manuscript. All the authors have critically revised and approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Deepika Sankaran.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplement Table 1: Description of characteristics among infants treated with intravitreal bevacizumab for ROP.

41372_2022_1489_MOESM2_ESM.jpg

Supplement Table 2: Description of echocardiographic features, respiratory support, and pulmonary vasodilator therapy before and after intravitreal bevacizumab treatment for ROP.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Park, L., Donohue, L., Lakshminrusimha, S. et al. Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension. J Perinatol (2022). https://doi.org/10.1038/s41372-022-01489-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41372-022-01489-0

Search

Quick links